Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
REMODULIN vs CIRCANOL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Treprostinil is a synthetic prostacyclin analog that directly vasodilates pulmonary and systemic arterial beds, inhibits platelet aggregation, and suppresses smooth muscle proliferation.
CIRCANOL (flupentixol) is a thioxanthene derivative that acts as a dopamine D1/D2 receptor antagonist, with higher affinity for D2 receptors, and also exhibits antagonism at serotonin 5-HT2 receptors. It modulates neurotransmission in the mesolimbic and mesocortical pathways, reducing positive symptoms of schizophrenia and exerting antidepressant effects at low doses via presynaptic dopamine receptor blockade.
Pulmonary arterial hypertension (WHO Group I) to improve exercise capacity and reduce symptoms,Off-label: Severe Raynaud's phenomenon, digital ischemia, and salvage therapy for PAH in patients failing other prostacyclins
Schizophrenia (maintenance therapy),Other psychotic disorders,Depression (low-dose augmentation in resistant cases)
Continuous subcutaneous infusion: Initially 1.25 ng/kg/min; increase by 1.25 ng/kg/min every week for first 4 weeks, then by 2.5 ng/kg/min every week as tolerated. Intravenous infusion: same dosing.
4 mg orally once daily.
Terminal elimination half-life is approximately 4 hours (range 2-7 hours) following continuous subcutaneous infusion; clinical context: requires continuous infusion due to short half-life.
Terminal elimination half-life is 14-18 hours in patients with normal renal function; prolonged in renal impairment.
Hepatic metabolism via CYP2C8 and CYP2C9 (major), with minor contributions from CYP2C19 and CYP2D6; major metabolite is a glucuronide conjugate.
Primarily hepatic via CYP2D6 and CYP3A4, forming metabolites including N-dealkylated and sulfoxide derivatives; undergoes extensive first-pass metabolism.
Renal: 20-30% as unchanged drug; fecal: 70-80% as metabolites (via biliary elimination).
Primarily renal (70-90% unchanged) with minor biliary/fecal (5-15%)
Approximately 58% bound to human plasma proteins, primarily to albumin.
40-50% bound to albumin and α1-acid glycoprotein
Volume of distribution (Vd) is 1.3 L/kg (range 0.8-2.0 L/kg); clinical meaning: extensive distribution into tissues, exceeding total body water.
1.2-1.8 L/kg; indicates extensive extravascular distribution, possibly due to tissue binding.
Subcutaneous: approximately 100% bioavailable compared to intravenous; oral: negligible (not administered orally).
Oral: 60-75% due to first-pass metabolism
No dosage adjustment required for renal impairment.
No dose adjustment required for GFR ≥30 m L/min; not recommended for use if GFR <30 m L/min.
Mild to moderate hepatic impairment (Child-Pugh class A or B): no adjustment. Severe hepatic impairment (Child-Pugh class C): contraindicated.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose to 2 mg once daily; Child-Pugh C: not recommended.
Not established; safety and efficacy in pediatric patients have not been studied.
Not approved for pediatric use; safety and efficacy not established.
No specific dose adjustment recommended; use with caution due to age-related renal/hepatic decline.
Start at 2 mg orally once daily; increase to 4 mg as tolerated based on response and renal function.
None. However, infusion site reactions (pain, erythema, induration) and risk of catheter-related bloodstream infections are significant concerns.
None
Sudden discontinuation may worsen PAH; taper if possible.,Infusion site reactions are common; avoid extravasation.,Risk of bleeding due to antiplatelet effects; use with caution in patients with peptic ulcer disease or on anticoagulants.,Hepatic impairment may increase exposure; dosage adjustment may be needed.,May cause systemic hypotension; monitor blood pressure.
Extrapyramidal symptoms (acute dystonia, akathisia, parkinsonism); tardive dyskinesia with long-term use; neuroleptic malignant syndrome; QT interval prolongation; increased mortality in elderly patients with dementia-related psychosis; seizures; hepatic impairment; hematologic effects (leukopenia, neutropenia); anticholinergic effects; orthostatic hypotension; hyperprolactinemia.
Known hypersensitivity to treprostinil or any excipient,Patients with severe hepatic impairment (Child-Pugh class C) due to lack of safety data
Comatose states; CNS depression; severe liver disease; blood dyscrasias; pheochromocytoma; known hypersensitivity to flupentixol or other thioxanthenes; concurrent use with dopamine agonists (except in Parkinson's disease psychosis).
There are no known food interactions with treprostinil. However, patients should maintain a balanced diet as part of overall PAH management. Grapefruit juice has not been reported to interact, but always consult with a healthcare provider.
Avoid grapefruit and grapefruit juice as they may increase drug levels and risk of side effects. No other significant food interactions. Maintain adequate hydration to prevent hypotension.
Teriprostinil (REMODULIN) is contraindicated in pregnancy due to teratogenic effects in animal studies (increased cardiovascular and skeletal malformations). There are no adequate human data; however, based on animal findings, fetal risk cannot be excluded, particularly in the first trimester. In later trimesters, risks include potential fetal harm from maternal hypotension and hypoxia.
First trimester: Evidence of human fetal harm based on retrospective studies showing increased risk of congenital anomalies (cardiac defects, neural tube defects) with first-trimester exposure. Second and third trimesters: Risk of fetal hypotension, neonatal respiratory depression, and withdrawal syndrome with chronic use; avoid near term due to risk of premature ductus arteriosus closure.
It is unknown if teriprostinil is excreted in human milk. M/P ratio not established. Due to potential for serious adverse reactions in nursing infants, breastfeeding is not recommended during treatment and for at least 48 hours after the last dose.
Small amounts excreted into breast milk (M/P ratio approximately 0.3-0.5). Considered compatible with breastfeeding due to limited oral bioavailability in infants; however, monitor infant for sedation or poor feeding.
Pregnancy is a contraindication; thus no dose adjustments are applicable. However, if used in exceptional circumstances, plasma volume expansion in pregnancy may alter drug distribution, but specific dose recommendations are lacking. Use is not recommended.
Increased volume of distribution and renal clearance in pregnancy may necessitate higher doses to maintain therapeutic effect; however, due to fetal risks, use lowest effective dose for shortest duration. No standard dose adjustment; individualize based on clinical response and tolerability.
REMODULIN (treprostinil) is a prostacyclin analog used for pulmonary arterial hypertension (PAH). Avoid abrupt discontinuation due to risk of rebound pulmonary hypertension. Monitor for infusion site reactions and bleeding risk due to antiplatelet effects. Dose titration should be guided by PAH symptoms and side effects. Use with caution in patients with hepatic impairment.
Circanol (ergoloid mesylates) is a vasodilator used primarily for age-related cognitive decline. Monitor for orthostatic hypotension, especially in elderly patients. Onset of benefit may take several weeks; discontinue if no response after 3-6 months. Avoid use in patients with a history of psychosis or severe hypotension. Can be used as adjunctive therapy for dementia but not a first-line agent.
Do not stop taking this medication suddenly; sudden cessation may cause worsening of symptoms.,Report any signs of bleeding (e.g., easy bruising, nosebleeds, blood in urine or stool) to your healthcare provider.,If using subcutaneous infusion, rotate injection sites to prevent site reactions and infection.,Store medication as directed; do not freeze or expose to excessive heat.,Avoid activities that increase bleeding risk, such as contact sports, until you discuss with your doctor.
Take Circanol exactly as prescribed; do not stop abruptly.,Rise slowly from sitting or lying to prevent dizziness or falls.,Report any fainting, rapid heart rate, or severe headache immediately.,Avoid alcohol as it may worsen side effects like dizziness and low blood pressure.,Improvement in symptoms may take 4-12 weeks; continue medication as directed even if no immediate benefit.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about REMODULIN vs CIRCANOL, answered by our medical review team.
REMODULIN is a Prostacyclin Vasodilator that works by Treprostinil is a synthetic prostacyclin analog that directly vasodilates pulmonary and systemic arterial beds, inhibits platelet aggregation, and suppresses smooth muscle proliferation.. CIRCANOL is a Vasodilator (Peripheral) that works by CIRCANOL (flupentixol) is a thioxanthene derivative that acts as a dopamine D1/D2 receptor antagonist, with higher affinity for D2 receptors, and also exhibits antagonism at serotonin 5-HT2 receptors. It modulates neurotransmission in the mesolimbic and mesocortical pathways, reducing positive symptoms of schizophrenia and exerting antidepressant effects at low doses via presynaptic dopamine receptor blockade.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between REMODULIN and CIRCANOL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of REMODULIN is: Continuous subcutaneous infusion: Initially 1.25 ng/kg/min; increase by 1.25 ng/kg/min every week for first 4 weeks, then by 2.5 ng/kg/min every week as tolerated. Intravenous infusion: same dosing.. The standard adult dose of CIRCANOL is: 4 mg orally once daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between REMODULIN and CIRCANOL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. REMODULIN is classified as Category C. Teriprostinil (REMODULIN) is contraindicated in pregnancy due to teratogenic effects in animal studies (increased cardiovascular and skeletal malformations). There are no adequate . CIRCANOL is classified as Category C. First trimester: Evidence of human fetal harm based on retrospective studies showing increased risk of congenital anomalies (cardiac defects, neural tube defects) with first-trimes. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.